Medication info
Sitadown Tablet 100 mg (Sitagliptin Hydrochloride Monohydrate)

Sitadown Tablet 100 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.37mg / 1 tablet
Manufacturer / importer
Hyundai Pharmaceutical Co., Ltd.
Appearance
Bright yellow-orange round film-coated tablets
Packaging
100 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202102465 · Approved 2021.03.19 · Insurance code 642004980

Summary

Main use
Improves blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For monotherapy or combination therapy, administer 100 mg once daily; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Hyundai Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in type 2 diabetes mellitus

  • Difficulty in controlling blood sugar in patients with type 2 diabetes
View approved original text

This medication is used to help patients with type 2 diabetes control their blood sugar levels. It can be administered alone in conjunction with diet and exercise therapy, and if the initial treatment is insufficient, it can be used in combination with metformin. Additionally, it can be used as an adjunctive treatment in conjunction with other antidiabetic medications such as sulfonylureas, thiazolidinediones, and insulin when controlling blood sugar is difficult. This medication helps improve blood sugar control when various monotherapy or combination therapies are not sufficient. It improves the health of patients through effective blood sugar management.

How to take

Adult dose

For monotherapy or combination therapy, administer 100 mg once daily; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication can cause severe allergic reactions. If you experience symptoms such as skin rash, difficulty breathing, or swelling of the face or neck during treatment, you should stop taking the medication immediately and consult a doctor. There is a risk of developing pancreatitis, a serious inflammation of the pancreas, while taking this medication. If you experience abdominal pain, nausea, or vomiting, you should visit a hospital immediately. Patients with type 1 diabetes or diabetic ketoacidosis should not take this medication, and it should not be used by those with an allergy to it. Patients with impaired kidney function may require dosage adjustments and should take the medication as per their doctor's instructions. There may be an increased risk of hypoglycemia when this medication is used in conjunction with other antidiabetic drugs, so be cautious of hypoglycemic symptoms if used together with insulin or sulfonylureas. During treatment, side effects such as headaches, upper respiratory infections, nasopharyngitis, diarrhea, abdominal pain, and other minor issues may occur, and it is recommended to consult a doctor if these symptoms persist. This medication is not recommended for use by pregnant or breastfeeding women, and its safety has not been established for children and adolescents under 18 years of age. Elderly patients may have decreased kidney function, so regular kidney function tests should be conducted before and after taking the medication, and dosage adjustments may be necessary. In case of overdose, monitoring such as gastrointestinal decontamination and ECG may be necessary, and some drugs may be removed through dialysis. This medication has relatively low interactions with other drugs, but caution is needed as the blood concentration may increase when co-administered with cyclosporine. If severe joint pain or blistering skin symptoms occur during treatment, you should immediately inform your doctor and discontinue the medication in such cases. While this medication has been confirmed to have cardiovascular safety, you should consult healthcare professionals if any unusual symptoms occur during treatment.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • nasopharyngitis
  • upper respiratory infection
  • headache
  • diarrhea
  • abdominal pain
Show 31 more
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe joint pain with disability
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute kidney failure
  • rash
  • urticaria
  • cutaneous vasculitis
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight container to keep out the air, and it is best to store it at room temperature between 1 to 30 degrees Celsius. Proper storage will maintain the effectiveness of the medication and prevent deterioration.

Appearance and packaging

Appearance

Bright yellow-orange round film-coated tablets

Package unit

100 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.